Zynerba Pharmaceuticals Inc. (Nasdaq: ZYNE) reported disappointing results from a Phase 2 STOP clinical trial of ZYN002. The stock price lost 61 cents to close at $6.42.
Zynerba Pharmaceuticals reports disappointing trial results
August 14, 2017 at 18:03 PM EDT
